Wells Fargo & Company MN lessened its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 12.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 114,186 shares of the medical instruments supplier’s stock after selling 16,579 shares during the quarter. Wells Fargo & Company MN owned about 0.61% of LeMaitre Vascular worth $3,565,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its holdings in LeMaitre Vascular by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 927,465 shares of the medical instruments supplier’s stock valued at $22,843,000 after buying an additional 19,128 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of LeMaitre Vascular by 6.5% during the first quarter. Vanguard Group Inc. now owns 660,331 shares of the medical instruments supplier’s stock worth $16,264,000 after purchasing an additional 40,448 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of LeMaitre Vascular by 45.8% during the second quarter. Conestoga Capital Advisors LLC now owns 565,069 shares of the medical instruments supplier’s stock worth $17,641,000 after purchasing an additional 177,379 shares in the last quarter. Thomson Horstmann & Bryant Inc. grew its holdings in shares of LeMaitre Vascular by 1.8% during the second quarter. Thomson Horstmann & Bryant Inc. now owns 365,977 shares of the medical instruments supplier’s stock worth $11,425,000 after purchasing an additional 6,638 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 35.4% during the first quarter. AQR Capital Management LLC now owns 219,888 shares of the medical instruments supplier’s stock worth $5,416,000 after purchasing an additional 57,525 shares in the last quarter. 66.75% of the stock is owned by institutional investors and hedge funds.
Shares of LeMaitre Vascular, Inc. (NASDAQ LMAT) opened at 37.20 on Friday. The company has a market cap of $707.62 million, a P/E ratio of 53.14 and a beta of 0.67. LeMaitre Vascular, Inc. has a 12 month low of $19.70 and a 12 month high of $39.88. The firm has a 50-day moving average price of $37.81 and a 200 day moving average price of $32.53.
LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.05. The company had revenue of $24.80 million for the quarter, compared to analysts’ expectations of $25.49 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. LeMaitre Vascular’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the firm earned $0.17 earnings per share. Equities analysts predict that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current year.
LeMaitre Vascular announced that its board has initiated a share buyback plan on Thursday, July 27th that authorizes the company to buyback $7.50 million in shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 1.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.
Several brokerages have recently commented on LMAT. Benchmark Co. lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday. First Analysis downgraded LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 target price for the company. in a research report on Friday. Canaccord Genuity restated a “hold” rating and issued a $30.00 target price on shares of LeMaitre Vascular in a research report on Monday, October 9th. Zacks Investment Research downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday, September 28th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $32.00 target price (up previously from $29.00) on shares of LeMaitre Vascular in a research report on Sunday, July 30th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $33.00.
In other LeMaitre Vascular news, insider David B. Roberts sold 48,317 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $33.12, for a total value of $1,600,259.04. Following the sale, the insider now owns 30,105 shares of the company’s stock, valued at approximately $997,077.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 10,000 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.62, for a total value of $336,200.00. Following the completion of the sale, the chief executive officer now directly owns 3,436,808 shares in the company, valued at approximately $115,545,484.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 373,121 shares of company stock worth $12,825,992. Corporate insiders own 23.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Wells Fargo & Company MN Has $3.57 Million Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/lemaitre-vascular-inc-lmat-shares-sold-by-wells-fargo-company-mn.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.